Zydus Cadila has got the US health regulator’s final approval for marketing its Metronidazole tablets that are used in the treatment of infections caused by bacteria or parasites.

The company has said in a regulatory filing that it has received “the final approval from the United States Food and Drug Administration (USFDA) to market Metronidazole tablets USP in strengths of 250 mg and 500 mg.”

It further said that the drug will be produced at the group’s formulations manufacturing facility at Baddi.

Read EquityPandit’s Nifty Pharma Outlook for this week